Chymotrypsin is a protease that is commonly used as a standard for protein crystallization and as a model system for studying serine proteases. Unliganded bovine α-chymotrypsin was crystallized at neutral pH using ammonium sulphate as the precipitant, resulting in crystals that conform to P6 5 symmetry with unit cell parameters that have not been reported previously. Inspection of crystallographic interfaces revealed that the major interface between any two molecules in the crystal lattice represents the interface of the biological dimer, as previously observed for crystals of unliganded α-chymotrypsin grown at low pH in space group P2 1 .
Introduction
Chymotrypsin is a serine endopeptidase secreted from the pancreas, and it is involved in proteolytic digestion. Chymotrypsinogen A is activated via hydrolysis of the Arg15-Ile16 peptide bond by trypsin to produce π-chymotrypsin. Autolytic cleavage of π-chymotrypsin at peptide bonds 13-14, 146-147, and 148-149 then follows to produce α-chymotrypsin, which consists of three separate polypeptides cross-linked by five disulphide bonds [1] . Chymotrypsin was one of the first protein structures solved by X-ray crystallography, and was the first solved structure of a protease [2] . Researchers quickly discovered that chymotrypsin can easily be crystallized using ammonium sulphate as a precipitant, often with lower pH (<4.5), leading to crystal forms conforming to the space group P2 1 , while at higher pH (>4.5), crystal forms usually conform to the space group P4 2 2 1 2, with the latter crystal form primarily used for crystallization with a ligand. Since this discovery, a number of other crystal forms have been reported. A summary of representative published crystal forms is presented in Table S1 . Given its long history of study and ease of purification, chymotrypsin has been used as a model system for several purposes. Chymotrypsin is often used in combination with other proteins as a control to study protein crystallization itself, such as probing general crystallization techniques as well as general seeding techniques. In addition, many other proteases, such as the proteasome, elastases, cathepsins, and calpain, have proven difficult to study in vitro due to problems in purification. As such, chymotrypsin is often used as a model for studying ligand-protease interactions, especially with regard to structure-guided drug design [3] [4] [5] . Here, we report a previously undocumented crystal form of α-chymotrypsin (Table 1) solved by X-ray crystallography to a resolution of 1.86 Å in the space group P6 5 . 
Materials and Methods

Macromolecule Production
TLCK (Tosyl-L-lysyl-chloromethane hydrochloride)-treated α-chymotrypsin A isolated from bovine pancreas was purchased from Worthington Biochemical Corporation (Lakewood, NJ, USA) as a dialyzed (1 mM HCl), lyophilized powder (product code: CDTLCK) and dissolved in 0.1 M HEPES pH 7.0 to a final concentration of 20 mg/ml.
Amino acids 14, 15, 147, and 148 (underlined) were removed during processing of chymotrypsinogen A to produce α-chymotrypsin.
Crystallization
Protein was crystallized by vapour-diffusion using the hanging drop method at 16 • C. Crystals formed as rods with a maximum dimension of approximately 400 µm after 1 month with 2 M ammonium sulphate as the reservoir solution. Complete details of the crystallization conditions are given in Table 2 . Prior to data collection, crystals were cryoprotected in Paratone-N (Hampton Research) and flash cooled in liquid nitrogen. 
Data Collection and Processing
X-ray diffraction data were collected at 13000 eV from a single crystal using the MX1 beamline [6] at the Australian Synchrotron. A total of 179 frames were collected at 1 • intervals with 1 • oscillation. Data were processed using iMosflm (CCP4i, Oxford, UK) [7] . Data collection and processing statistics are shown in Table 3 . Table 3 . Data collection and processing. Values for the outer shell are given in parentheses. All data were collected from a single crystal.
Diffraction Source
Australian Synchrotron Beamline MX1
184.95 
Structure Solution and Refinement
The structure of α-chymotrypsin was solved by molecular replacement using Phaser-MR [9] with chain A of the 4Q2K (with all non-protein atoms removed) as the search model. The final solution contained four copies of the search model in the asymmetric unit, with a translation function Z (TFZ) score of 50.7, and log-likelihood gain (LLG) of 10450. Refinement of atomic coordinates was performed by successive iterations of refinement using phenix.refine [10] and manual rebuilding in Coot [11] . Torsion-angle non-crystallographic symmetry (NCS) restraints were applied. Anisotropic refinement of B-factors was restricted to torsion-liberation-screw (TLS) groups [12] . Both NCS and TLS groups were defined automatically using phenix.refine. Optimization of the relative X-ray/stereochemistry and X-ray/B-factor weights was performed in the final rounds of refinement. Refinement statistics are shown in Table 4 . The structure factors and atomic coordinates for the final model were deposited at the Protein Data Bank (PDB) under accession 6DI8. Molecular graphic images were produced using PyMOL (v2.0.7, Schrodinger, LLC, New York City, NY, USA) [13] . 
Results and Discussion
The structure of bovine α-chymotrypsin was solved in space group P6 5 using data to 1.86 Å. The unit cell parameters (Table 3) have not been reported previously for crystals of α-chymotrypsin with this symmetry, indicating that this is a novel crystal form Residues 1 to 245 were confidently modelled into the electron density, with the exceptions of Ser14, Arg15, Thr147, and Asn148, which were removed during chymotrypsin activation and autolysis. The final model displays favourable geometric statistics; the only Ramachandran outlier present in each molecule is Ile99 (electron density for Ile99 shown in Figure 1 ), which forms part of the S2 site and its conformation is well supported by strong electron density. All five disulphide bonds are clearly observed in each subunit. The arrangement of subunits is such that the N-terminal peptide (residues 1-13) is at the centre of the asymmetric unit, with the active site facing out away from the centre. The asymmetric unit contains an arrangement of four subunits of α-chymotrypsin exhibiting two-fold non-crystallographic rotational symmetry through three mutually perpendicular axes (Figure 2 The structure of bovine α-chymotrypsin was solved in space group P65 using data to 1.86 Å. The unit cell parameters (Table 3) have not been reported previously for crystals of α-chymotrypsin with this symmetry, indicating that this is a novel crystal form. The asymmetric unit contains an arrangement of four subunits of α-chymotrypsin exhibiting two-fold non-crystallographic rotational symmetry through three mutually perpendicular axes (Figure 2) . Residues 1 to 245 were confidently modelled into the electron density, with the exceptions of Ser14, Arg15, Thr147, and Asn148, which were removed during chymotrypsin activation and autolysis. The final model displays favourable geometric statistics; the only Ramachandran outlier present in each molecule is Ile99 (electron density for Ile99 shown in Figure 1 ), which forms part of the S2 site and its conformation is well supported by strong electron density. All five disulphide bonds are clearly observed in each subunit. The arrangement of subunits is such that the N-terminal peptide (residues 1-13) is at the centre of the asymmetric unit, with the active site facing out away from the centre. Due to this being a new crystal form, the crystallographic interfaces for this P6 5 structure of unliganded α-chymotrypsin were analysed using PISA (Proteins, Interfaces, Structures and Assemblies) [14] (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) and compared to the structure of unliganded α-chymotrypsin solved in spacegroup P2 1 (PDB ID: 4CHA), which contains two chymotrypsin molecules in the asymmetric unit [15] . Table 5 details the interfaces for α-chymotrypsin solved in spacegroup P6 5 . Interfaces for the P2 1 structure are listed in Table S2 . Overall, 77% of interface residues for the P6 5 crystal form are at interfaces in the P2 1 structure. Interface 1 is largely conserved in each of the structures, involving 11 hydrogen bonds and 1 salt bridge, and is formed between molecules of the asymmetric unit of the P2 1 structure, but between symmetry-mates of our P6 5 crystal (Figure 3) . This is the dimerization interface of α-chymotrypsin, which is formed by the active
site face of each monomer [15, 16] . Thus, the tetramer asymmetric unit observed in P6 5 contains four subunits; each individual subunit forms a biological assembly (dimer) with crystallographic symmetry mates. Interface 2 also consists of the same residues for the P6 5 and P2 1 forms. Multiple bonding interactions are observed at this interface for the P6 5 crystal form, with 10 hydrogen bonds and 2 salt bridges identified. For the P2 1 crystal form, however, only a single salt bridge is present. This is consistent with tighter packing at the central interfaces of the P6 5 crystal form. Although most of the residues involved in interface formation are shared between these structures, interfaces 3-6 were not conserved, due to the evident difference in crystal packing. The residues forming each of these interfaces in space group P6 5 were shared across several interfaces of the P2 1 crystal form. Due to this being a new crystal form, the crystallographic interfaces for this P65 structure of unliganded α-chymotrypsin were analysed using PISA (Proteins, Interfaces, Structures and Assemblies) [14] (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) and compared to the structure of unliganded α-chymotrypsin solved in spacegroup P21 (PDB ID: 4CHA), which contains two chymotrypsin molecules in the asymmetric unit [15] . Table 5 details the interfaces for α-chymotrypsin solved in spacegroup P65. Interfaces for the P21 structure are listed in Table S2 . Overall, 77% of interface residues for the P65 crystal form are at interfaces in the P21 structure. Interface 1 is largely conserved in each of the structures, involving 11 hydrogen bonds and 1 salt bridge, and is formed between molecules of the asymmetric unit of the P21 structure, but between symmetry-mates of our P65 crystal (Figure 3) . This is the dimerization interface of α-chymotrypsin, which is formed by the active site face of each monomer [15, 16] . Thus, the tetramer asymmetric unit observed in P65 contains four subunits; each individual subunit forms a biological assembly (dimer) with crystallographic symmetry mates. Interface 2 also consists of the same residues for the P65 and P21 forms. Multiple bonding interactions are observed at this interface for the P65 crystal form, with 10 hydrogen bonds and 2 salt bridges identified. For the P21 crystal form, however, only a single salt bridge is present. This is consistent with tighter packing at the central interfaces of the P65 crystal form. Although most of the residues involved in interface formation are shared between these structures, interfaces 3-6 were not conserved, due to the evident difference in crystal packing. The residues forming each of these interfaces in space group P65 were shared across several interfaces of the P21 crystal form. 
